Cancer & SURVIVEiT News

Category Filter:

SURVIVEiT Breast Cancer Patient Stories Plus Stats On Genetic Stats

Breast Cancer Patient Stories Plus Stats On Genetic Stats

October 6, 2021

October is breast cancer awareness month, so we’re shedding light on this particular type of cancer. Aside from skin cancers, breast cancer is the most common type of cancer women…

TNBC Foundation Explains 3 Myths About Triple Negative Breast Cancer

March 3, 2021

Triple Negative Breast Cancer Awareness is all about bringing attention to this particular type of breast cancer and understanding what makes it different from other types of breast cancer. The…

FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast

June 30, 2020

FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast cancer On June 29, 2020, the Food and Drug Administration approved a new fixed-dose combination of pertuzumab, trastuzumab, and…

FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast

June 2, 2020

FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer On April 22, 2020, the Food and Drug Administration granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY, Immunomedics,…

FDA approves tucatinib for patients with HER2-positive metastatic breast cancer

June 2, 2020

FDA approves tucatinib for patients with HER2-positive metastatic breast cancer On April 17, 2020, the Food and Drug Administration approved (TUKYSA, Seattle Genetics, Inc.) in combination with trastuzumab and capecitabine,…

FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast

June 2, 2020

FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer On April 22, 2020, the Food and Drug Administration granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY, Immunomedics,…

FDA approves tucatinib for patients with HER2-positive metastatic breast cancer

June 2, 2020

FDA approves tucatinib for patients with HER2-positive metastatic breast cancer On April 17, 2020, the Food and Drug Administration approved (TUKYSA, Seattle Genetics, Inc.) in combination with trastuzumab and capecitabine,…

Breast Cancer News | Some Patients NED After New Combo

May 5, 2020

Big news for breast cancer patients! The percentage of patients that had a complete response (meaning NO EVIDENCE OF DISEASE!) to Imfinzi + Lynparza + chemo are significantly increasing in…

FDA approves neratinib for metastatic HER2-positive breast cancer

February 27, 2020

FDA approves neratinib for metastatic HER2-positive breast cancer On February 25, 2020, the Food and Drug Administration approved neratinib (NERLYNX, Puma Biotechnology, Inc.) in combination with capecitabine for adult patients…